Drugs / Grippol Quadrivalent
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06385821 | Sep 2022 → Jun 2023 | swine influenza | NPO Petrovax | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-09-12 | NPO Petrovax | Regulatory Grippol® Quadrivalent influenza vaccine is now approved for children from 6 months petrovax.com ↗
In August 2023, the updated instruction for human use was approved by the Ministry of Health of the Russian Federation. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-09-12 | NPO Petrovax | Grippol® Quadrivalent influenza vaccine is now approved for children from 6 months petrovax.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Grippol Quadrivalent | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06385821 ↗ |
| Modality | Vaccine | “influenza quadrivalent inactivated subunit adjuvant vaccine” NCT06385821 ↗ |
| Route | Intramuscular | “Solution for intramuscular and subcutaneous administration” NCT06385821 ↗ |
| Route | Subcutaneous | “Solution for intramuscular and subcutaneous administration” NCT06385821 ↗ |